You are here

AusPAR: Acalabrutinib

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

10 March 2020
AusPAR Details
AusPAR
Active Ingredient
Acalabrutinib
Product Name
Calquence
Sponsor
AstraZeneca Pty Ltd
Submission Number
PM-2019-04317-1-6
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
17 February 2020
Publication Date

10 March 2020